LYNDHURST N.J., Jan. 18, 2018 /PRNewswire/ — In relation to the recently announced decision by the Patent Trial and Appeal Board (“PTAB”) on Amerigen Pharmaceuticals Limited’s inter partes review (IPR2016-00286), challenging U.S. Patent 8,822,438 B2 (owned by Janssen Oncology, Inc.),…
